
James Lumsdaine
Interim Chief Executive Officer
Only a small percentage of cancer patients receive genetic biomarker testing that could match them with targeted treatments demonstrated to improve outcomes. At Imagia Canexia Health, we pair the latest advances in oncology with machine learning to provide oncology professionals with the insights needed to inform targeted treatment decisions.
Together, we’re making precision oncology more accessible.
At Imagia Canexia Health, we make high-quality cancer genomic information accessible and affordable with our clinically-validated assays, informatics, and support. Visit our Investor Relations page for information for stockholders, potential investors, and financial analyst.
Interim Chief Executive Officer
Chief Financial Officer
Chief Medical Officer
Chief Science Officer
Chief Business Officer
Executive Vice President Corporate & Public Affairs
Vice President, Oncology & Clinical Strategy